Electronic Patient-Reported Outcomes

How it works

Benefits

Preparation

Comparisons

Evidence quality

Highlighted claims

• ePRO-based monitoring collects patient-reported symptoms through digital devices during or between visits. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• ePRO-based monitoring can generate algorithm-driven alerts for clinicians or patients. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• Direct evidence for ePRO monitoring in HCC patients receiving immunotherapy remains limited. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• The weekly survey was designed to balance clinical usefulness with participant burden. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• Routine symptom monitoring based mainly on outpatient clinician assessment can miss symptoms arising between visits. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
• Prior cancer trials have shown that ePRO monitoring can improve quality of life, physical function, symptom control, and overall survival. — Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial